Bioinks for tissue engineering
Photopolymerizing hydrogel bioinks with PRP and thrombin receptor agonist peptide-6 address the challenge of incorporating temperature-sensitive molecules in 3D printing, creating biocompatible, electroconductive scaffolds that promote vascularization and tissue regeneration with controlled activation and predictable mechanical properties.
Patent Information
- Application Number
- PCT/IB2023/055490
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Filing Date
- 2023-05-29
- Publication Date
- 2024-12-05
AI Technical Summary
Existing bioinks for 3D printing of tissue scaffolds face challenges in incorporating temperature-sensitive bioactive molecules like PRP due to high temperatures involved in FDM processing, leading to loss of biological potency and unsuitable mechanical properties.
Development of photopolymerizing hydrogel bioinks incorporating PRP and thrombin receptor agonist peptide-6 for controlled activation, which are electroconductive and include materials like PEDOTT PSS, polyaniline, and zinc oxide particles, allowing for 3D printing without high temperatures and providing predictable mechanical properties.
Enables the creation of biocompatible, electroconductive 3D scaffolds with controlled activation of PRP, promoting vascularization and antimicrobial effects, maintaining biological potency and facilitating tissue regeneration with predictable mechanical properties.
Smart Images

Figure 000001 
Figure 000002 
Figure 000003
Abstract
Description
[0001] BIOINKS FOR TISSUE ENGINEERING
[0002] TECHNICAL FIELD
[0003] The present invention relates generally to tissue engineering using bioinks, in particular bioinks for repair and replacement of diseased and damaged tissue.
[0004] BACKGROUND
[0005] There have been significant advances in tissue engineering in recent years, for the repair and replacement of diseased and damaged tissue. Tissue engineering typically involves the use of scaffolds composed of synthetic or natural polymer materials to support tissue growth either in vitro or in situ.
[0006] It has been proposed to use bioinks that can be direct 3D printed to form tissue scaffolds. There are, however, challenges in developing bioinks that are suitable for use in 3D printing techniques whilst also exhibiting desired properties for tissue scaffolds to enable repair and regeneration of tissue, including good biocompatibility, appropriate mechanical and structural properties and the biofunctional properties required for the intended use.
[0007] In particular, whilst bioink compositions have been proposed for use in FDM 3D printing techniques, the relatively high temperatures involved in FDM processing severely limit the possibilities of incorporating temperature sensitive bioactive molecules, such as platelet rich plasma (PRP).
[0008] PRP has been recognised to promote vascularisation and promote rapid regeneration of tissues. Commercial use of PRP so far has been accompanied by autologous or exogenous thrombin to enable the formation of a gel. However, this approach, with thrombin-based activation, is rapid and is not ideal for biofabrication with 3D printing as the gel will lose its biological potency with time. SUMMARY OF INVENTION
[0009] Embodiments of the invention are generally aimed at providing bioinks that are suitable for forming tissue scaffolds (and other structures) using direct 3D printing techniques, and relevant biofabrication methods, whilst offering desired biofunctional properties.
[0010] With this aim in mind, it is proposed that embodiments of the invention provide bioinks that are photopolymerizing hydrogels (e.g. cross-linked with photo-initiators) incorporating bioactive molecules that include, for example, PRP. The hydrogels are preferably also electroconductive. The use of a photopolymerizing hydrogel enables the 3D printed material to be cured (by photo activation) without requiring the higher temperatures associated with more conventional FDM processing that might be incompatible with the viability of the bioactive molecules.
[0011] In a first aspect, the invention provides a bioink for use in direct 3D printing of biocompatible structures, the bioink comprising: a photopolymerizing hydrogel; and bioactive molecules (e.g. temperature sensitive bioactive molecules including platelet rich plasma (PRP)).
[0012] In some embodiments, the bioink includes a thrombin receptor agonist peptide-6 for activating the PRP. Adopting this approach, rather more conventional thrombin-based activation of the PRP, means the activation can be better controlled.
[0013] In some embodiments, the hydrogel is electroconductive.
[0014] In some embodiments, the hydrogel comprises poly(3,4-ethylenedioxythiophene) polystyrene sulfonate and / or polyaniline.
[0015] In some embodiments, the hydrogel is crosslinked with photo-initiators to provide the desired photopolymerization characteristic.
[0016] In some embodiments, the hydrogel comprises a dispersible and soluble electroconductive polymer, homogenised within the hydrogel with Acrylic Acid (family groups) and Polyethylene Glycol / (poly)acrylate / diacrylate (family groups).
[0017] In some embodiments, the bioink further comprises one or more of: L-arginine, amino acids, peptides and proteins. In some embodiments, the hydrogel comprises zinc oxide particles, for example as a dispersion. The particles are preferably micro- and / or nano-particles.
[0018] In some embodiments, the hydrogel comprises Kaolin.
[0019] In some embodiments, the bioink further comprises collagen and / or collagen peptides.
[0020] In some embodiments, the bioink comprises biocompatible Polydimethylsiloxane, silicone family groups, its co-polymers, and / or silicon dioxide.
[0021] In some embodiments the bioink has antimicrobial properties.
[0022] Hydrogel bioinks incorporating PRP and thrombin receptor agonist peptide-6 for activating the PRP may also be useful in cases where photo-curing of the bioink is not required.
[0023] Accordingly, in a second aspect, the invention provides a bioink comprising: a polymeric scaffold; platelet rich plasma (PRP); and thrombin receptor agonist peptide-6 for activating the PRP.
[0024] The polymeric scaffold may include a hydrogel.
[0025] Bioinks in accordance with embodiments of the first and second aspects above can be used, for example to create 3D scaffolds, wound dressings, medical devices (e.g. implantable devices) and other structures and components for medical uses (especially where there is a requirement for biocompatibility). These structures may be formed, for example, using direct 3D printing techniques.
[0026] The invention also provides 3D scaffolds, wound dressings, medical devices and other medical structures and components formed from a bioink according to the first or second aspect above.
[0027] The skilled person will appreciate that the features described and defined in connection with the aspects of the invention and the embodiments thereof may be combined in any combination, regardless of whether the specific combination is expressly mentioned herein. Thus, all such combinations are considered to be made available to the skilled person. DETAILED DESCRIPTION OF AN EMBODIMENT
[0028] An embodiment is described below by way of example.
[0029] This embodiment relates to a bioink that is an electroconductive, photopolymerising hydrogel and incorporates bioactive molecules, in particular that include autologous platelet rich plasma (PRP).
[0030] This exemplary bioink is designed to be used to produce biomimetic 3D scaffolds with suitable techniques such as 3D printing to repair and replace diseased or damaged tissue.
[0031] Through introducing variations to the ratio of core constituents of the hydrogel, as well as through variations in 3D patterns which can be introduced through 3D modelling, the 3D scaffolds can be produced with predictable variations in strength, and Youngs modulus. Therefore, a range of predictable mechanical properties can be obtained to match biological tissue of interest and intended applications of the bioink and the resultant 3D printed structures.
[0032] The electroconductivity of the scaffolds may be based on incorporation in the bioink composition of PEDOTT PSS (i.e. poly(3,4-ethylenedioxythiophene) polystyrene sulfonate) and / or polyaniline. The incorporation of such materials to give the resultant structure electroconductive properties is desirable in some application to help ‘reboot’ endogenous electrophysiology or enable application of external pulse current to the tissue. This can help the scaffold facilitate rapid regeneration and tissue homeostasis as well as providing antimicrobial effects.
[0033] For example, once a 3D scaffold is fabricated, a pulsed voltage (or current) electrical signal can be applied to the scaffold by an external device to reset electroconductivity through the scaffold or enable the body’s endogenous electrical system to reactivate and lead natural tissue repair.
[0034] Bioink based 3D scaffolds in accordance with the embodiment incorporate PRP to promote rapid vascularisation. The presence of a patient's own PRP as a core constituent of biomaterials, along with electroconductivity can be particularly effective in facilitating tissue vascularisation of 3D tissue constructs whilst attenuating any adverse foreign body reactions, both major reasons of implant failure. Rather than using thrombin-based activation of the PRP, which is conventional, in this example the PRP is activated using a peptide, specifically thrombin receptor agonist peptide-6 (Ser-Phe-Leu-Leu-Arg-Asn-NH2). This allows a more controlled activation of the PRP, which is desirable so that the gel does not lose its biological potency too rapidly. Bioactive constituents within the hydrogel can also include, for example, L-arginine to enable activation of nitric oxide pathways.
[0035] Bioinks in accordance with embodiments of the present invention can be employed to produce bio-hybrid, electroconductive, patient specific 3D printed tissue at-the-point-of-care, for example to those awaiting organ donations, and therefore efficaciously address conditions arising from diseased or damaged tissue. This may be done, for example, in a clinical theatre setting using appropriate 3D printing apparatus.
[0036] Embodiments of the photopolymeric bioink can also be utilized, for example, for endoscopic delivery to enable tissue repair / replacement within the body.
[0037] Other embodiments of bioinks in accordance with the invention can be used to perform in-vitro cell responsive studies as well as development of in-vivo pre-clinical models.
[0038] The skilled person will understand that various modifications and additions can be made to the example described above without departing from the spirit and scope of the present invention.
Claims
CLAIMS:
1. A bioink for use in direct 3D printing of biocompatible structures, the bioink comprising: a photopolymerizing, electroconductive hydrogel; and bioactive molecules including platelet rich plasma (PRP).
2. A bioink for use in direct 3D printing of biocompatible structures, the bioink comprising: a photopolymerizing hydrogel; and temperature sensitive bioactive molecules.
3. A bioink according to claim 2, wherein the temperature sensitive bioactive molecules comprise platelet rich plasma (PRP).
4. A bioink according to claim 1 or claim 3, comprising thrombin receptor agonist peptide- 6 for activating the PRP.
5. A bioink comprising : a polymeric scaffold; platelet rich plasma (PRP); and thrombin receptor agonist peptide-6 for activating the PRP.
6. A bioink according to claim 5, comprising a hydrogel.
7. A bioink according to any one of claims 2 to 4 or claim 6, wherein the hydrogel is electroconductive .
8. A bioink according to any one of claims 1 to 4 or claim 6 or claim 7, wherein the hydrogel comprises poly(3,4-ethylenedioxythiophene) polystyrene sulfonate and / or polyaniline.
9. A bioink according to claim 8, wherein the poly(3,4-ethylenedioxythiophene) polystyrene sulfonate and / or polyaniline is crosslinked with photo-initiators.
10. A bioink according to any one of claims 1 to 4 or claims 6 to 9, wherein the hydrogel comprises photo-initiators.
11. A bioink according to any one of claims 1 to 4 or claims 6 to 10, wherein the hydrogel comprises zinc oxide particles as a dispersion.
12. A bioink according to any one of claims 1 to 4 or claims 6 to 11, wherein the hydrogel comprises kaolin.
13. A bioink according to any one of the preceding claims, wherein the hydrogel comprises a dispersible and soluble electroconductive polymer, homogenised within the hydrogel with Polyethylene Glycol (family groups), (Poly)AcrylateZDiacrylate (family groups), and / or Acrylic Acid (family groups).
14. A bioink according to any one of the preceding claims, further comprising one or more of: L-arginine, amino acids, peptides and proteins.
15. A bioink according to any one of the preceding claims, further comprising collagen and / or collagen peptides.
16. A bioink according to any one of the preceding claims, wherein the bioink comprises biocompatible Polydimethylsiloxane, silicone family groups, its co-polymers, and / or silicon dioxide.
17. Use of a bioink according to any one of the preceding claims to create a 3D scaffold or a wound dressing.
18. Use according to claim 17, wherein the 3D scaffold or wound dressing is formed by direct 3D printing.
19. A 3D scaffold formed from a bioink according to any one of claims 1 to 16.
20. A wound dressing formed from a bioink according to any one of claims 1 to 16.
21. Use of a bioink according to any one of claims 1 to 16 to create a medical device or medical structure.
22. Use according to claim 21, wherein the medical device or structure is formed by direct 3D printing.
23. A medical device or structure formed from a bioink according to any one of claims 1 to 16.
24. A medical device or structure according to claim 23, wherein the device or structure is intended for implantation in the human or animal body.
Citation Information
Patent Citations
Bioinks for tissue engineering
GB2607602A
Bioinks for tissue engineering
GB2609543A
